Roxana Grunenwald, Yuva Krishnapillai, and Elia Ahmadi, three Gen Z venture capitalists from Haus Fund, organized a black-tie event on the SS Jeremiah O’Brien, a World War II Liberty ship. Approximately 150 guests attended the event, where samples of peptides, including a GHK-Cu topical cream and dissolvable sublingual strips from Afterglow, were provided. The venue was chosen to symbolize American industrial strength and to advocate for reshoring the pharmaceutical supply chain to the United States.
The event took place during a period of debate regarding peptide regulation. The US Department of Health and Human Services (HHS) recently issued an interim policy decision permitting certain unapproved peptides for compounding. This decision is controversial, as FDA career scientists have not endorsed it, citing insufficient evidence for the safety or efficacy of the experimental peptides. Industry experts have expressed concerns that this policy could undermine the established clinical trial framework.
The HHS decision potentially allows telehealth providers and compounding pharmacies to bypass traditional approval processes, creating a parallel market with less stringent regulation. The organizers of the event used this context to emphasize their call for American-made peptides, aiming to address sourcing concerns associated with the gray market.
✨ This summary was generated by AI from the outlets' reporting listed below. It is not independently verified and may contain errors — check the original sources. How BrevFeed works →
One email each morning: the day's tech stories, clustered across outlets and summarized. No account needed.
One email a day. Unsubscribe in one click, any time.
Spend a few minutes, get the whole day. Every topic's top stories in one hands-free rundown — listen, watch, or read the transcript.
▶ Play today's briefNew every morning, and the back catalogue is archived by date.
Three Gen Z venture capitalists from Haus Fund hosted an event on a WWII ship to advocate for domestic peptide manufacturing. This event occurred amidst a controversial HHS policy decision allowing certain unapproved peptides for compounding, a move not endorsed by FDA scientists due to safety and efficacy concerns.